Review



recombinant human mesothelin standard  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems recombinant human mesothelin standard
    <t>Mesothelin</t> expression in PaC and ovarian cancer cell lines by WB ( a , b ), and with or without PNGaseF digestion ( c ). ( a ) MSLN expression in cell lysates (top), stripping and reblotting with GADPH as loading control (bottom): 20 µg total protein loaded per lane; ( b ) MSLN expression in secretion media: 25 µg total protein loaded per lane. For ( a , b ) 25 ng rMSLN were used as a positive control; ( c ) MSLN from 10 µg protein lysates or 25 ng rMSLN detected with an anti-MSLN antibody (clone MN-1) under reducing conditions (left) and WB on 50 ng rMSLN detected with Aleuria aurantia lectin (fucose detection) under non-reducing conditions (right); ND: not digested; D: digested.
    Recombinant Human Mesothelin Standard, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+mesothelin+standard/pmc09405996-98-2-8?v=R%26D+Systems
    Average 93 stars, based on 7 article reviews
    recombinant human mesothelin standard - by Bioz Stars, 2026-06
    93/100 stars

    Images

    1) Product Images from "Characterization of Mesothelin Glycosylation in Pancreatic Cancer: Decreased Core Fucosylated Glycoforms in Pancreatic Cancer Patients’ Sera"

    Article Title: Characterization of Mesothelin Glycosylation in Pancreatic Cancer: Decreased Core Fucosylated Glycoforms in Pancreatic Cancer Patients’ Sera

    Journal: Biomedicines

    doi: 10.3390/biomedicines10081942

    Mesothelin expression in PaC and ovarian cancer cell lines by WB ( a , b ), and with or without PNGaseF digestion ( c ). ( a ) MSLN expression in cell lysates (top), stripping and reblotting with GADPH as loading control (bottom): 20 µg total protein loaded per lane; ( b ) MSLN expression in secretion media: 25 µg total protein loaded per lane. For ( a , b ) 25 ng rMSLN were used as a positive control; ( c ) MSLN from 10 µg protein lysates or 25 ng rMSLN detected with an anti-MSLN antibody (clone MN-1) under reducing conditions (left) and WB on 50 ng rMSLN detected with Aleuria aurantia lectin (fucose detection) under non-reducing conditions (right); ND: not digested; D: digested.
    Figure Legend Snippet: Mesothelin expression in PaC and ovarian cancer cell lines by WB ( a , b ), and with or without PNGaseF digestion ( c ). ( a ) MSLN expression in cell lysates (top), stripping and reblotting with GADPH as loading control (bottom): 20 µg total protein loaded per lane; ( b ) MSLN expression in secretion media: 25 µg total protein loaded per lane. For ( a , b ) 25 ng rMSLN were used as a positive control; ( c ) MSLN from 10 µg protein lysates or 25 ng rMSLN detected with an anti-MSLN antibody (clone MN-1) under reducing conditions (left) and WB on 50 ng rMSLN detected with Aleuria aurantia lectin (fucose detection) under non-reducing conditions (right); ND: not digested; D: digested.

    Techniques Used: Expressing, Stripping Membranes, Control, Positive Control

    Mesothelin peptides detected by UPLC-ESI-QTof. Crossed boxes indicate peptides identified in Capan-2 (C), AsPC-1 (A), HPAF-II (H), Ovcar-8 (H), rMSLN (rM) and deglycosylated rMSLN (dM).
    Figure Legend Snippet: Mesothelin peptides detected by UPLC-ESI-QTof. Crossed boxes indicate peptides identified in Capan-2 (C), AsPC-1 (A), HPAF-II (H), Ovcar-8 (H), rMSLN (rM) and deglycosylated rMSLN (dM).

    Techniques Used: Sequencing

    Mesothelin expression in pancreatic tissue lysates by WB under non-reducing conditions. Each number represents a different patient in each condition. A total of 20 µg protein was loaded per lane, and 25 ng rMSLN used as a positive control. All membranes were equally exposed to chemiluminescence for lane comparison. Control samples included two healthy pancreas (H) and pancreatic non-tumor tissues adjacent to the cancer region from cholangiocarcinomas (C), from duodenum adenocarcinomas (D), from ampulloma (A) and from PaC (NT). Cancer tissues included thirty-one PaC of different stages and other tumors: one ampulloma (A) and one cholangiocarcinoma (C)).
    Figure Legend Snippet: Mesothelin expression in pancreatic tissue lysates by WB under non-reducing conditions. Each number represents a different patient in each condition. A total of 20 µg protein was loaded per lane, and 25 ng rMSLN used as a positive control. All membranes were equally exposed to chemiluminescence for lane comparison. Control samples included two healthy pancreas (H) and pancreatic non-tumor tissues adjacent to the cancer region from cholangiocarcinomas (C), from duodenum adenocarcinomas (D), from ampulloma (A) and from PaC (NT). Cancer tissues included thirty-one PaC of different stages and other tumors: one ampulloma (A) and one cholangiocarcinoma (C)).

    Techniques Used: Expressing, Positive Control, Comparison, Control



    Similar Products

    recombinant human mesothelin standard  (R&D Systems)
    93
    R&D Systems recombinant human mesothelin standard
    <t>Mesothelin</t> expression in PaC and ovarian cancer cell lines by WB ( a , b ), and with or without PNGaseF digestion ( c ). ( a ) MSLN expression in cell lysates (top), stripping and reblotting with GADPH as loading control (bottom): 20 µg total protein loaded per lane; ( b ) MSLN expression in secretion media: 25 µg total protein loaded per lane. For ( a , b ) 25 ng rMSLN were used as a positive control; ( c ) MSLN from 10 µg protein lysates or 25 ng rMSLN detected with an anti-MSLN antibody (clone MN-1) under reducing conditions (left) and WB on 50 ng rMSLN detected with Aleuria aurantia lectin (fucose detection) under non-reducing conditions (right); ND: not digested; D: digested.
    Recombinant Human Mesothelin Standard, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+mesothelin+standard/pmc09405996-98-2-8?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    recombinant human mesothelin standard - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Mesothelin expression in PaC and ovarian cancer cell lines by WB ( a , b ), and with or without PNGaseF digestion ( c ). ( a ) MSLN expression in cell lysates (top), stripping and reblotting with GADPH as loading control (bottom): 20 µg total protein loaded per lane; ( b ) MSLN expression in secretion media: 25 µg total protein loaded per lane. For ( a , b ) 25 ng rMSLN were used as a positive control; ( c ) MSLN from 10 µg protein lysates or 25 ng rMSLN detected with an anti-MSLN antibody (clone MN-1) under reducing conditions (left) and WB on 50 ng rMSLN detected with Aleuria aurantia lectin (fucose detection) under non-reducing conditions (right); ND: not digested; D: digested.

    Journal: Biomedicines

    Article Title: Characterization of Mesothelin Glycosylation in Pancreatic Cancer: Decreased Core Fucosylated Glycoforms in Pancreatic Cancer Patients’ Sera

    doi: 10.3390/biomedicines10081942

    Figure Lengend Snippet: Mesothelin expression in PaC and ovarian cancer cell lines by WB ( a , b ), and with or without PNGaseF digestion ( c ). ( a ) MSLN expression in cell lysates (top), stripping and reblotting with GADPH as loading control (bottom): 20 µg total protein loaded per lane; ( b ) MSLN expression in secretion media: 25 µg total protein loaded per lane. For ( a , b ) 25 ng rMSLN were used as a positive control; ( c ) MSLN from 10 µg protein lysates or 25 ng rMSLN detected with an anti-MSLN antibody (clone MN-1) under reducing conditions (left) and WB on 50 ng rMSLN detected with Aleuria aurantia lectin (fucose detection) under non-reducing conditions (right); ND: not digested; D: digested.

    Article Snippet: A commercial recombinant human mesothelin standard (rMSLN, #3265-MS, R&D Systems, Minneapolis, MN, USA) which is produced in a murine myeloma cell line (NS0-derived) was used throughout the study as a control, both for the MSLN expression and glycosylation.

    Techniques: Expressing, Stripping Membranes, Control, Positive Control

    Mesothelin peptides detected by UPLC-ESI-QTof. Crossed boxes indicate peptides identified in Capan-2 (C), AsPC-1 (A), HPAF-II (H), Ovcar-8 (H), rMSLN (rM) and deglycosylated rMSLN (dM).

    Journal: Biomedicines

    Article Title: Characterization of Mesothelin Glycosylation in Pancreatic Cancer: Decreased Core Fucosylated Glycoforms in Pancreatic Cancer Patients’ Sera

    doi: 10.3390/biomedicines10081942

    Figure Lengend Snippet: Mesothelin peptides detected by UPLC-ESI-QTof. Crossed boxes indicate peptides identified in Capan-2 (C), AsPC-1 (A), HPAF-II (H), Ovcar-8 (H), rMSLN (rM) and deglycosylated rMSLN (dM).

    Article Snippet: A commercial recombinant human mesothelin standard (rMSLN, #3265-MS, R&D Systems, Minneapolis, MN, USA) which is produced in a murine myeloma cell line (NS0-derived) was used throughout the study as a control, both for the MSLN expression and glycosylation.

    Techniques: Sequencing

    Mesothelin expression in pancreatic tissue lysates by WB under non-reducing conditions. Each number represents a different patient in each condition. A total of 20 µg protein was loaded per lane, and 25 ng rMSLN used as a positive control. All membranes were equally exposed to chemiluminescence for lane comparison. Control samples included two healthy pancreas (H) and pancreatic non-tumor tissues adjacent to the cancer region from cholangiocarcinomas (C), from duodenum adenocarcinomas (D), from ampulloma (A) and from PaC (NT). Cancer tissues included thirty-one PaC of different stages and other tumors: one ampulloma (A) and one cholangiocarcinoma (C)).

    Journal: Biomedicines

    Article Title: Characterization of Mesothelin Glycosylation in Pancreatic Cancer: Decreased Core Fucosylated Glycoforms in Pancreatic Cancer Patients’ Sera

    doi: 10.3390/biomedicines10081942

    Figure Lengend Snippet: Mesothelin expression in pancreatic tissue lysates by WB under non-reducing conditions. Each number represents a different patient in each condition. A total of 20 µg protein was loaded per lane, and 25 ng rMSLN used as a positive control. All membranes were equally exposed to chemiluminescence for lane comparison. Control samples included two healthy pancreas (H) and pancreatic non-tumor tissues adjacent to the cancer region from cholangiocarcinomas (C), from duodenum adenocarcinomas (D), from ampulloma (A) and from PaC (NT). Cancer tissues included thirty-one PaC of different stages and other tumors: one ampulloma (A) and one cholangiocarcinoma (C)).

    Article Snippet: A commercial recombinant human mesothelin standard (rMSLN, #3265-MS, R&D Systems, Minneapolis, MN, USA) which is produced in a murine myeloma cell line (NS0-derived) was used throughout the study as a control, both for the MSLN expression and glycosylation.

    Techniques: Expressing, Positive Control, Comparison, Control